Skip to main content
Sinocelltech Group Limited logo

Sinocelltech Group Limited — Investor Relations & Filings

Ticker · 688520 ISIN · CNE100003ZL3 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 659 across all filing types
Latest filing 2022-04-26 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 688520

About Sinocelltech Group Limited

https://www.sinocelltech.com/

Sinocelltech Group Limited focuses on the research, development, and commercialization of innovative biologics, including monoclonal antibodies, recombinant proteins, and vaccine candidates. The company's product pipeline addresses therapeutic areas such as oncology, autoimmune disorders, hematology, and infectious diseases. Key offerings include recombinant human coagulation factor VIII for hemophilia A and a range of biosimilars. Sinocelltech leverages an integrated technology platform encompassing early-stage discovery through to large-scale industrial production. This infrastructure supports the development of high-quality biological medicines aimed at addressing unmet medical needs through advanced protein engineering and cell line development.

Recent filings

Filing Released Lang Actions
独立董事提名人声明（王晓川）
Board/Management Information Classification · 95% confidence The document is a formal statement nominating an independent director candidate for the company's board. It details the qualifications, independence criteria, and compliance with relevant laws and regulations for the nominee. There is no financial data, no report attached or referenced as published, and no mention of voting results or meeting materials. This document is related to board/management information, specifically about a board nomination. Therefore, it fits best under the category of Board/Management Information (MANG). The document length is short and focused on nomination, not a full report or announcement of voting results.
2022-04-26 Chinese
中信证券股份有限公司关于北京神州细胞生物技术集团股份公司2022年度申请综合授信额度并提供担保的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed verification opinion from a sponsoring institution (中信证券股份有限公司) regarding a company's (北京神州细胞生物技术集团股份公司) application for a comprehensive credit limit and provision of guarantees for the year 2022. It includes background information, financial data, internal decision procedures, board and independent directors' opinions, and the sponsor's opinion. The document is not a financial report itself but an audit or verification opinion related to financing and guarantees. It does not contain full financial statements or quarterly results but focuses on the review and approval process of credit and guarantee applications. This fits the definition of an Audit Report / Information (AR) as it is a standalone audit/verification report related to financial and regulatory compliance, not a full annual or interim report, nor a simple announcement or certification. FY 2022
2022-04-26 Chinese
神州细胞第一届监事会第二十二次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of Beijing Shenzhou Cell Biotechnology Group Co., Ltd. It details the approval of various reports and proposals including the 2021 Annual Report, 2021 Supervisory Board Work Report, 2021 Financial Statements, 2022 Financial Budget, 2021 Fundraising Use Report, 2021 Internal Control Evaluation Report, 2021 Profit Distribution Plan, 2022 Supervisory Board Remuneration Plan, 2022 Daily Related Party Transactions, borrowing from controlling shareholder, Supervisory Board re-election, and the 2022 Q1 Report. The document states that the actual reports are disclosed on the Shanghai Stock Exchange website and that these resolutions will be submitted to the shareholders' meeting for approval. The document itself does not contain the full reports or substantive financial data but is a formal announcement of the Supervisory Board's resolutions regarding these reports and proposals. The document length is 3255 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document is best classified as a Regulatory Filing (RNS) as it is a formal regulatory announcement of Supervisory Board resolutions and approvals, not the reports themselves.
2022-04-26 Chinese
神州细胞关于续聘公司2022年度审计机构的公告
Audit Report / Information Classification · 95% confidence The document is an announcement regarding the reappointment of the auditing firm PwC Zhongtian for the fiscal year 2022. It details the qualifications, independence, and integrity of the audit firm and the procedures followed by the audit committee, independent directors, and the board of directors to approve this reappointment. There is no actual audit report or financial statements included, nor is there detailed financial data or analysis. The document is relatively short (3,719 characters) and serves as a formal announcement of the auditor appointment for the upcoming fiscal year. This fits the category of an Audit Report / Information announcement, specifically about the appointment of the audit firm, rather than the audit report itself or an annual report. Therefore, the appropriate classification is AR (Audit Report / Information). FY 2022
2022-04-26 Chinese
独立董事提名人声明（何为）
Board/Management Information Classification · 95% confidence The document is a nomination statement for an independent director candidate at Beijing Shenzhou Cell Biotechnology Group Co., Ltd. It details the qualifications, independence criteria, and legal compliance of the nominee. There is no financial data, no report or announcement of financial results, no voting results, no management changes announcement per se, but it is related to board/management information specifically about director nomination. This fits best under Board/Management Information (MANG) as it concerns the nomination of a board member.
2022-04-26 Chinese
神州细胞2021年年度报告
Annual Report Classification · 100% confidence The document is titled "2021 年年度报告" which translates to "2021 Annual Report". It contains detailed financial data, management discussion and analysis, company overview, risk factors, governance, and audited financial statements. The presence of an audit report with an unqualified opinion from PwC, detailed financial metrics, quarterly financial data, and extensive management commentary confirms this is a comprehensive yearly report. The document length is about 15,000 characters, indicating it is the full report, not just an announcement or summary. Therefore, the document fits the definition of an Annual Report (10-K). FY 2021
2022-04-26 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.